Product Description: Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.
Applications: Cancer-Kinase/protease
Formula: C17H14O4
References: [1]Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9(6):e99988./[2]Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89(3):351-7.
CAS Number: 117570-53-3
Molecular Weight: 282.29
Compound Purity: 99.80
Research Area: Cancer; Infection
Solubility: 7.5% sodium bicarbonate : 6.67 mg/mL (ultrasonic)/DMSO : 7.14 mg/mL (ultrasonic)
Target: IFNAR;Influenza Virus;STING
English
Deutsch
